NLRP3 and chronic obstructive pulmonary disease: Decrease level of IL-1β, IL-18, TNF-α, NLRP3, ASC, Procaspase-1, Caspase-1 and GSDMD after LP17 treatment compared to COPD mice.Reduction of bronchial wall thickening and inflammatory cell infiltration after LP17 treatment compared to COPD mice.